Comparative Pharmacology
Head-to-head clinical analysis: LANSOPRAZOLE versus PREVACID IV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LANSOPRAZOLE versus PREVACID IV.
LANSOPRAZOLE vs PREVACID IV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor that inhibits gastric acid secretion by binding to the H+/K+ ATPase enzyme (proton pump) in gastric parietal cells, preventing the final step of acid production.
Lansoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by specific inhibition of the (H+, K+)-ATPase enzyme system at the secretory surface of gastric parietal cells. This action is dose-related and leads to inhibition of both basal and stimulated gastric acid secretion.
15-30 mg orally once daily; 30 mg IV over 30 minutes once daily (when oral not possible).
30 mg intravenous infusion over 30 minutes once daily for up to 7 days; may switch to oral therapy when patient can tolerate oral intake.
None Documented
None Documented
Clinical Note
moderateDexlansoprazole + Clodronic acid
"The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderateLansoprazole + Clodronic acid
"The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Lansoprazole."
Clinical Note
moderateDexlansoprazole + Alendronic acid
"The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderateTerminal elimination half-life: 1.5-2 hours (increased to 3-6 hours in elderly, hepatic impairment).
Terminal elimination half-life is approximately 1.5–2 hours in healthy individuals; however, the pharmacodynamic half-life (duration of acid suppression) is longer (up to 24 hours) due to accumulation in parietal cell canaliculi.
Renal (14-23% as metabolites); biliary/fecal (major route, ~60% as metabolites and parent drug).
Primarily hepatic metabolism via CYP2C19 and CYP3A4; approximately 75% excreted in urine as metabolites, with less than 1% as unchanged drug; about 20% eliminated in feces via bile.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor
Lansoprazole + Alendronic acid
"The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Lansoprazole."